Human Intravenous Immunoglobulin (IVIG) Preparations Degranulate Human Neutrophils in Vitro

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1998 Nov 20

PMID 9822286

Citations 10

Authors

J L Teeling

E R de Groot

A J Eerenberg

W K Bleeker

G van Mierlo

L A Aarden

C E Hack

Affiliations

Soon will be listed here.

Abstract

IVIG preparations have biological effects in vivo that are not fully understood. Possible effects include the property to stimulate Fc receptors on various cell types. To study whether IVIG may interact with neutrophils we developed an in vitro system, in which neutrophils, in whole blood or purified, were incubated with IVIG and assessed for degranulation by measuring the release of elastase and lactoferrin in culture medium. All commercially available IVIG preparations tested induced degranulation of neutrophils when incubated for 2 h at therapeutically relevant concentrations. In studies with blocking antibodies against Fc receptors (FcR), this degranulation was shown to be dependent on Fc gammaRII, whereas Fc gammaRIII had no effect. Experiments with purified neutrophils as well as binding experiments with labelled IVIG preparations indicated that neutrophil degranulation resulted from a direct interaction of IVIG with neutrophils. Using gel filtration fractions, it was found that polymeric and dimeric IgG present in IVIG was mainly responsible for the degranulation. We suggest that degranulation of neutrophils may contribute to the (side)effects of IVIG treatment in vivo.

Citing Articles

Activated neutrophils: A next generation cellular immunotherapy.

Kumbhojkar N, Mitragotri S Bioeng Transl Med. 2025; 10(1):e10704.

PMID: 39801751 PMC: 11711228. DOI: 10.1002/btm2.10704.

Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin.

Masso-Silva J, Sakoulas G, Olay J, Groysberg V, Geriak M, Nizet V Front Immunol. 2022; 13:993720.

PMID: 36341409 PMC: 9632428. DOI: 10.3389/fimmu.2022.993720.

Common variable immunodeficiency patients display elevated plasma levels of granulocyte activation markers elastase and myeloperoxidase.

Litzman J, Chovancova Z, Bejdak P, Litzman M, Hel Z, Vlkova M Int J Immunopathol Pharmacol. 2019; 33:2058738419843381.

PMID: 30968712 PMC: 6458674. DOI: 10.1177/2058738419843381.

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Rowley T, Peters S, Aylott M, Griffin R, Davies N, Healy L Commun Biol. 2018; 1:146.

PMID: 30272022 PMC: 6138732. DOI: 10.1038/s42003-018-0149-9.

Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders.

Prezzo A, Cavaliere F, Milito C, Bilotta C, Iacobini M, Quinti I Blood Transfus. 2018; 17(2):103-111.

PMID: 30036181 PMC: 6476744. DOI: 10.2450/2018.0043-18.

References

Veys P, Macey M, Owens C, Newland A . Neutropenia following intravenous immunoglobulin. Br Med J (Clin Res Ed). 1988; 296(6639):1800. PMC: 2546267. DOI: 10.1136/bmj.296.6639.1800-a. View

Tankersley D, Preston M, Finlayson J . Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988; 25(1):41-8. DOI: 10.1016/0161-5890(88)90088-0. View

Falk R, Terrell R, Charles L, Jennette J . Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990; 87(11):4115-9. PMC: 54058. DOI: 10.1073/pnas.87.11.4115. View

Otsuka Y, Nagano K, Hori K, Hayashi H, Watanabe N, Niitsu Y . Inhibition of neutrophil migration by tumor necrosis factor. Ex vivo and in vivo studies in comparison with in vitro effect. J Immunol. 1990; 145(8):2639-43. View

Creasey A, Stevens P, Kenney J, Allison A, Warren K, Catlett R . Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock. 1991; 33(2):84-91. View

Hechtman D, Cybulsky M, Fuchs H, Baker J, Gimbrone Jr M . Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol. 1991; 147(3):883-92. View

Greenman J, Tutt A, George A, Pulford K, Stevenson G, Glennie M . Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors. Mol Immunol. 1991; 28(11):1243-54. DOI: 10.1016/0161-5890(91)90011-8. View

Dwyer J . Manipulating the immune system with immune globulin. N Engl J Med. 1992; 326(2):107-16. DOI: 10.1056/NEJM199201093260206. View

Ben-Chetrit E, Putterman C . Transient neutropenia induced by intravenous immune globulin. N Engl J Med. 1992; 326(4):270-1. DOI: 10.1056/NEJM199201233260413. View

10.

Nuijens J, Abbink J, Wachtfogel Y, Colman R, Eerenberg A, Dors D . Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med. 1992; 119(2):159-68. View

11.

Fridman W, Bonnerot C, Daeron M, Amigorena S, Teillaud J, Sautes C . Structural bases of Fc gamma receptor functions. Immunol Rev. 1992; 125:49-76. DOI: 10.1111/j.1600-065x.1992.tb00625.x. View

12.

Tuijnman W, Capel P, van de Winkel J . Human low-affinity IgG receptor Fc gamma RIIa (CD32) introduced into mouse fibroblasts mediates phagocytosis of sensitized erythrocytes. Blood. 1992; 79(7):1651-6. View

13.

Hack C, Hart M, van Schijndel R, Eerenberg A, Nuijens J, Thijs L . Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun. 1992; 60(7):2835-42. PMC: 257242. DOI: 10.1128/iai.60.7.2835-2842.1992. View

14.

Niessen H, Verhoeven A . Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cell Signal. 1992; 4(5):501-9. DOI: 10.1016/0898-6568(92)90019-5. View

15.

van de Winkel J, Capel P . Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993; 14(5):215-21. DOI: 10.1016/0167-5699(93)90166-I. View

16.

Borregaard N, Lollike K, Kjeldsen L, Sengelov H, Bastholm L, Nielsen M . Human neutrophil granules and secretory vesicles. Eur J Haematol. 1993; 51(4):187-98. DOI: 10.1111/j.1600-0609.1993.tb00629.x. View

17.

Aukrust P, Froland S, Liabakk N, Muller F, Nordoy I, Haug C . Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994; 84(7):2136-43. View

18.

Mulder A, Heeringa P, Brouwer E, Limburg P, Kallenberg C . Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol. 1994; 98(2):270-8. PMC: 1534410. DOI: 10.1111/j.1365-2249.1994.tb06137.x. View

19.

de Haas M, Vossebeld P, von dem Borne A, Roos D . Fc gamma receptors of phagocytes. J Lab Clin Med. 1995; 126(4):330-41. View

20.

Vassilev T, Bineva I, Dietrich G, Kaveri S, Kazatchkine M . Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995; 8(3):405-13. DOI: 10.1006/jaut.1995.0032. View